<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033041</url>
  </required_header>
  <id_info>
    <org_study_id>STU00215570</org_study_id>
    <nct_id>NCT05033041</nct_id>
  </id_info>
  <brief_title>Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide</brief_title>
  <official_title>Comparison of Gastric Volumes by Gastric Ultrasound in Term Parturients Undergoing Scheduled Elective Cesarean Delivery With and Without Metoclopramide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our objective is to compare gastric volumes (mL) between women who receive metoclopramide&#xD;
      versus placebo prior to scheduled cesarean delivery in appropriately fasted patients. If&#xD;
      metoclopramide is found not to reduce gastric volumes this would inform future practice&#xD;
      guidelines for obstetric anesthesia, which currently recommends metoclopramide administration&#xD;
      prior to cesarean deliveries.&#xD;
&#xD;
      We hypothesize that metoclopramide given to women with appropriate fasting prior to cesarean&#xD;
      delivery does not result in any clinically significant reduction in gastric volume (mL) and&#xD;
      therefore does not provide any additional benefit for aspiration prophylaxis but may expose&#xD;
      patients to unnecessary side effects. A secondary objective will be to evaluate if gastric&#xD;
      volume is a significant predictor of intraoperative nausea and vomiting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled blinded study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Research pharmacy to prepare the study medication blinding the participant, care providers, investigator and outcomes assessor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in gastric volume (mL)</measure>
    <time_frame>30 minutes after administration of study drug</time_frame>
    <description>Change in gastric volume (mL) determined by ultrasound before and 30 minutes after administration of study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence (number of events) of nausea and vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of episodes (events) of intraoperative nausea and vomiting during cesarean delivery and post-operative nausea and vomiting after cesarean delivery (correlated to metoclopramide administration and gastric volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of adverse events (akathisia, dystonia, abdominal cramping, extrapyramidal symptoms) experienced between the two study groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Pregnancy</condition>
  <condition>Cesarean Section</condition>
  <condition>Aspiration</condition>
  <arm_group>
    <arm_group_label>Group 1 Study Drug Metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration of 10 mg metoclopramide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Study Drug Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous administration of sterile normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study drug metoclopramide</intervention_name>
    <description>Intravenous administration of 4 mg metoclopramide</description>
    <arm_group_label>Group 1 Study Drug Metoclopramide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study drug placebo administration</intervention_name>
    <description>Intravenous administration of placebo (sterile normal saline)</description>
    <arm_group_label>Group 2 Study Drug Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy (ASA Physical Status 2)&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Non-obese (BMI &lt;40 kg/m2)&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Term (&gt;37 week)&#xD;
&#xD;
          -  Non-laboring parturient&#xD;
&#xD;
          -  Single gestation&#xD;
&#xD;
          -  Scheduled for a cesarean delivery and NPO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic disease such as diabetes mellitus (type 1 or 2)&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  Abnormality of upper GI tract&#xD;
&#xD;
          -  History of GI tract related surgical procedures&#xD;
&#xD;
          -  Use of gastric motility medications&#xD;
&#xD;
          -  Active labor&#xD;
&#xD;
          -  Renal impairment (creatinine &gt;2)&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Cognitively impaired&#xD;
&#xD;
          -  History of QT prolongation&#xD;
&#xD;
          -  Use of general anesthesia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant undergoing cesarean section.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Banayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Banayan, MD</last_name>
    <phone>(312) 472-3585</phone>
    <email>jennifer.banayan@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital and Prentice Women's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Banayan, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration: Application to Healthy Patients Undergoing Elective Procedures: An Updated Report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. Anesthesiology. 2017 Mar;126(3):376-393. doi: 10.1097/ALN.0000000000001452.</citation>
    <PMID>28045707</PMID>
  </reference>
  <reference>
    <citation>MENDELSON CL. The aspiration of stomach contents into the lungs during obstetric anesthesia. Am J Obstet Gynecol. 1946 Aug;52:191-205.</citation>
    <PMID>20993766</PMID>
  </reference>
  <reference>
    <citation>Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016 Feb;124(2):270-300. doi: 10.1097/ALN.0000000000000935.</citation>
    <PMID>26580836</PMID>
  </reference>
  <reference>
    <citation>4. Knight M, Bunch K, Tuffnell D, Shakespeare J, Kotnis R, Kenyon S, Kurinczuk JJ (Eds.) on behalf of MBRRACE-UK. Saving Lives, Improving Mothers' Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2016-18. Oxford: National Perinatal Epidemiology Unit, University of Oxford 2020.</citation>
  </reference>
  <reference>
    <citation>Leus M, van de Ven A. IMAGES IN CLINICAL MEDICINE. An Acute Dystonic Reaction after Treatment with Metoclopramide. N Engl J Med. 2015 Oct;373(14):e16. doi: 10.1056/NEJMicm1412207.</citation>
    <PMID>26422744</PMID>
  </reference>
  <reference>
    <citation>Mishriky BM, Habib AS. Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. Br J Anaesth. 2012 Mar;108(3):374-83. doi: 10.1093/bja/aer509. Epub 2012 Feb 3. Review.</citation>
    <PMID>22307240</PMID>
  </reference>
  <reference>
    <citation>Paranjothy S, Griffiths JD, Broughton HK, Gyte GM, Brown HC, Thomas J. Interventions at caesarean section for reducing the risk of aspiration pneumonitis. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004943. doi: 10.1002/14651858.CD004943.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;2:CD004943.</citation>
    <PMID>20091567</PMID>
  </reference>
  <reference>
    <citation>Perlas A, Mitsakakis N, Liu L, Cino M, Haldipur N, Davis L, Cubillos J, Chan V. Validation of a mathematical model for ultrasound assessment of gastric volume by gastroscopic examination. Anesth Analg. 2013 Feb;116(2):357-63. doi: 10.1213/ANE.0b013e318274fc19. Epub 2013 Jan 9.</citation>
    <PMID>23302981</PMID>
  </reference>
  <reference>
    <citation>Van de Putte P, Perlas A. Ultrasound assessment of gastric content and volume. Br J Anaesth. 2014 Jul;113(1):12-22. doi: 10.1093/bja/aeu151. Epub 2014 Jun 3. Review.</citation>
    <PMID>24893784</PMID>
  </reference>
  <reference>
    <citation>Arzola C, Perlas A, Siddiqui NT, Carvalho JCA. Bedside Gastric Ultrasonography in Term Pregnant Women Before Elective Cesarean Delivery: A Prospective Cohort Study. Anesth Analg. 2015 Sep;121(3):752-758. doi: 10.1213/ANE.0000000000000818.</citation>
    <PMID>26097988</PMID>
  </reference>
  <reference>
    <citation>Arzola C, Perlas A, Siddiqui NT, Downey K, Ye XY, Carvalho JCA. Gastric ultrasound in the third trimester of pregnancy: a randomised controlled trial to develop a predictive model of volume assessment. Anaesthesia. 2018 Mar;73(3):295-303. doi: 10.1111/anae.14131. Epub 2017 Dec 19.</citation>
    <PMID>29265187</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Jennifer Banayan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Gastric Volume</keyword>
  <keyword>Ultrasound Measurement</keyword>
  <keyword>Aspiration Prevention</keyword>
  <keyword>Cesarean Section</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

